Surface Oncology Announces FDA Clearance of SRF617 and SRF388 INDs to Initiate Phase 1 Clinical Trials

NEXT STORY
Zai Lab Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Greenshoe Option
PREV STORY
Eurobio Scientific: full-year revenues up 17% to €59.1M
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

BioXcel Therapeutics Announces First Patient Enrolled in Phase 1b/2 RELEASE Trial of BXCL501 for the Treatment of Opioid Withdrawal Symptoms

author_avatar
NASDAQ Market News

Apellis Announces Submission of Pegcetacoplan Marketing Applications to FDA and EMA for Patients with PNH

author_avatar
NASDAQ Market News

Midatech receives Orphan Drug Designation for MTD119 from the European Medicines Agency

28 February 2018Midatech Pharma PLC("Midatech" or the "Company") Midatech receives Orphan Drug Designation for ...

author_avatar
NASDAQ Market News